MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - March 04, 2013) - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
management will present at two upcoming international investor conferences:
Credit Suisse Global Healthcare One-on-One Conference
Date: March 6, 2013
Venue: London, UK
Participants: Jens Holstein, Chief Financial Officer; Dr. Claudia Gutjahr-
Löser,
Head of Corporate Communications & Investor Relations
Barclays Global Healthcare Conference in Miami, FL, USA
Date: March 14, 2013, 9:00 am EDT (1:00 pm GMT, 2:00 pm CET)
Venue: Miami, FL, USA
Participants: Jens Holstein, Chief Financial Officer; Dr. Claudia Gutjahr-
Löser,
Head of Corporate Communications & Investor Relations
The PDF version of the presentations will be provided at
www.morphosys.com. The
link to the webcast will be filed under www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in
the pharmaceutical industry. By successfully applying this and other
patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment
of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT®, arYla®,
Ylanthia® and 100 billion high potentials® are registered
trademarks of
MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology
GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
concerning the
MorphoSys group of companies. The forward-looking statements contained
herein
represent the judgment of MorphoSys as of the date of this release and
involve
risks and uncertainties. Should actual conditions differ from the
Company's
assumptions, actual results and actions may differ from those
anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as
far as the wording of the relevant press release is concerned.
Media Release (PDF):
http://hugin.info/130295/R/1682744/550542.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1682744]
